Press release

« Older Entries

THERADIAG announces CE marking approval for its new i-Track10 automated analyzer for biotherapy monitoring

Croissy-Beaubourg, November 18, 2019, 8:00 am CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has obtained the CE marking for its i-Track10 automated analyzer for biotherapy monitoring. One of the key points of the agreement signed last April with IDS, which manufactures diagnostic […]

Theradiag and PredictImmune announce a strategic agreement French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease

Theradiag and PredictImmune announce a strategic agreement French speaking Europe to commercialise PredictSURE IBD™, the world’s first validated prognostic test for inflammatory bowel disease This exclusive deal with the French diagnostic specialist facilitates the first launch of PredictImmune’s prognostic tests in mainland Europe; and enables IBD patients in France, Belgium, Luxembourg and Switzerland to benefit […]

Theradiag announces improved results for H1 2019

Continued improvement in operating income Extraordinary income from non-recurring instrumentation sales generating investment capacity, to be reinvested in key strategic markets Cash position: €3.2 million, sufficient for upcoming investments   Croissy-Beaubourg, September 24, 2019, 5:45pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced its consolidated […]

Theradiag announces first-half revenue up 9%

Croissy-Beaubourg, July 18, 2019, 5.45 pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced its consolidated first-half revenues for the period ending June 30, 2019.   in €000   H1 2019   H1 2018   Change Revenue*   4,976   4,565   +9%               of […]

THERADIAG : Voting results of the Annual Ordinary and Extraordinary General Meeting

Croissy-Beaubourg, June 3, 2018, 6pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces the voting results of its Annual Ordinary and Extraordinary General Meeting, held on May 16th, 2019 at the offices of Fieldfisher Paris, 48 rue Cambon, 75001 Paris. PR_Theradiag_030619_Voting Results AGM VENG Final

Theradiag strengthens its presence in the United States on biotherapy monitoring

Croissy-Beaubourg, May 14, 2019, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialized in in vitro diagnostics and theranostics, is today announcing plans to accelerate its development in the United States, the world’s largest market for in vitro diagnostics and biotherapies. In this context, Theradiag signed a new contract with HalioDx, a French expert […]

Theradiag and HOB Biotech settle their legal dispute

Croissy-Beaubourg (France), April 4, 2019 5:45pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announced that it has entered into a settlement agreement with HOB Biotech to end their legal dispute. In 2015, HOB Biotech and Theradiag signed a series of agreements designed to organize a commercial cooperation […]

THERADIAG signs a development and distribution agreement with IMMUNODIAGNOSTIC SYSTEMS

THERADIAG will have access to IMMUNODIAGNOSTIC SYSTEMS’ latest generation IDS-i10® automated CLIA analysis technology, dedicated to biotherapy monitoring IMMUNODIAGNOSTIC SYSTEMS will market THERADIAG’s TRACKER® range in 33 countries Croissy-Beaubourg (France), April 1, 2019 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announced the signature of an agreement […]

Theradiag reports its 2018 full-year results

Growth of 17% in sales of Tracker kits for routine use Net loss before non-recurring items of €0.4 million, close to breakeven Cash position: €3.4 million   Croissy-Beaubourg, March 27, 2019 – 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialized in in vitro diagnostics and theranostics, has today announced its consolidated full-year results for the […]

Theradiag reports annual revenues for 2018 and its year-end cash position

Consolidated 2018 revenues: €8.9 million Continued growth in sales of Lisa Tracker® kits for routine use: 17% Cash position: €3.4 million   Croissy-Beaubourg, February 20, 2019, 5.45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specialiazing in in vitro diagnostics and theranostics, announced today its consolidated full-year revenues for 2018 and its cash position […]

« Précédent